JB Chemicals Bulk Deal: Promoter Sells 5.8% Stake For Rs 1,460 Crore
The promoter of JB Chemicals & Pharmaceuticals Ltd. sold 5.8% stake in the company for Rs 1,460 crore through an open market transaction on Thursday.
The New York and Hong Kong-based investment firm— Tau Investment Holdings offloaded 89.83 lakh shares or 5.8% at Rs 1625 apiece, according to a bulk deal data on NSE.
Tau Investment held 53.66% in the company as of December 2024.
Kotak Mahindra Mutual Fund mopped up 12.3 lakh shares or 0.79% stake at Rs 1,625 apiece.
On Wednesday, sources informed NDTV Profit that the pharmaceutical firm will sell up to 15.9 million shares in a block valued at Rs 2,576 crore. The shares were to be offered at a price of Rs 1,625 apiece, the sources had said.
In the quarter ended December 2024, JB Chemicals' consolidated net profit jumped 22% year-on-year to Rs 163 crore. The revenue grew 14% to Rs 963 crore in the same period.
Shares of JB Chemicals on Thursday closed 5.45% lower at Rs 1,615.70 apiece on the National Stock Exchange, compared to a 0.45% rise in the benchmark Nifty 50. The stock has fallen by 1.66% in the last 12 months but declined 12.39% on a year-to-date basis.
Thirteen out of the 15 analysts tracking the company have a 'buy' rating on the stock, one recommends 'hold' and another suggests 'sell', according to Bloomberg data. The average of 12-month analysts' price targets implies a potential upside of 33%.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.